Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Q: Paragraph: "Phony marijuana targeted by recent state legislation sounds worse than the real thing, if you believe Georgia's governor. Chase's Law strengthens a ban on ""synthetic marijuana,"" ground-up plant material laced with chemicals that mimic marijuana. Chase Burnett, the bill's namesake, was found dead in March in a hot tub at his Fayette County home, a packet of the drugs nearby. He was 16. The bill passed with overwhelming support. On March 27, Gov. Nathan Deal signed it into law. A press release warned of synthetic marijuana's dangers: ""As the usage has dramatically increased, instances of violence, bodily harm and even death have risen with it,"" it said. We've heard that the drug is nasty stuff. But what's this about violence, bodily harm and death? A Deal spokeswoman sent PolitiFact Georgia news stories and poison control data to prove the governor's point. We also talked to researchers and law enforcement officials and reviewed news stories and scientific studies. The form of synthetic marijuana that's sparking so much concern is sold at head shops and gas stations under brand names such as ""Spice"" and ""K2."" Georgia made it a felony to manufacture and sell it in 2010. Chase's Law tries to keep underground chemists from tweaking their recipes to get around state restrictions. There's little scholarly research on the drug, which appears to be new to the U.S. Federal labs first detected these drugs in November 2008, according to the Drug Enforcement Administration. The earliest U.S. news story we found about its rising popularity appeared in a Hutchinson Kan., newspaper in November 2009. All signs suggest that synthetic marijuana use is increasing dramatically, but data is in short supply. Workers at the American Association of Poison Control Centers began tracking synthetic marijuana calls in 2010 after they noticed more inquiries, a spokeswoman told PolitiFact Georgia. In 2010, they received 2,906 calls; in 2011, there were 6,959. About 11 percent of high school seniors reported using synthetic marijuana in the past year, according to 2011 results of an annual survey by the National Institute on Drug Abuse. It was the first time researchers asked about the drug. Existing data support Deal's claim that reports of bodily harm have climbed. Georgia Poison Center call data show 10 users were admitted to a hospital's critical care unit in 2010 after using the drug. Forty-five were admitted in 2011. Rapid heartbeat, agitation, drowsiness, vomiting, hallucinations and nausea were among the drug's most common effects, researchers have found. Media accounts report drug users injured in car crashes, falls and other accidents -- some fatal. Whether synthetic marijuana is directly responsible for deaths -- and whether they're increasing -- is a more complicated issue. We found no published studies on the drug's lethality, but there have been ""scattered reports of deaths,"" said Lloyd Johnston, a University of Michigan professor who conducted the National Institute on Drug Abuse survey. A count of news stories suggests there are more deadly cases. But whether the drug is a direct cause or contributing factor is not clear in some instances. Consider Burnett's death. Toxicology tests are still in the works. Whether the official cause of death was drowning, the drug or something else is unsettled. Georgia Bureau of Investigation spokesman John Bankhead told PolitiFact Georgia of two other recent deaths: We found other accounts of synthetic marijuana-related deaths. For example, a South Carolina coroner ruled that it was directly responsible for the October death of a college basketball player who collapsed during warm-up, according to multiple news accounts. PolitiFact Georgia found less support for Deal's claim about violence. We found no published studies on the subject. News stories, however, suggest there's cause for concern. For instance: To sum up: Evidence supports Deal's claim that use of the drug has ""dramatically increased,"" as has synthetic marijuana-related ""bodily harm."" Some evidence suggests that deaths have risen, too. The link between the drug and violence is less clear. News accounts suggest there is an increase in both, but we found so few cases it's hard to tell. Deal's statement could use clarification. Still, it earns a ." Claim: As the usage [of synthetic marijuana] has dramatically increased, instances of violence, bodily harm and even death have risen with it.

A: "Deal: Fake marijuana use rising, connected to death, violence and ""bodily harm"""
****
Q: Paragraph: Israel-based BrainStorm said on Monday a case report is being published in the February issue of "Muscle & Nerve" by the principal investigator and his colleagues at Hadassah Hospital in Jerusalem and a professor from the Mayo Clinic in Minnesota. The report is already available online. A 75 year-old-man diagnosed with both MG and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, was treated with BrainStorm's NurOwn cells. Both are neurodegenerative diseases. One month after receiving injections of the cells, the patient and his family reported significant improvement in cognition, speech, and muscle power. After six months, due to progression of weakness and deterioration in cognition, a repeat injection of NurOwn was performed. Again, improvements in the ALS functional rating scale were observed, the report said, adding that treatment with NurOwn appeared safe and well tolerated. "The results suggest that repeated therapy may maintain and enhance the clinical benefits of NurOwn cell therapy in neurological diseases," it said. Chaim Lebovits, president of BrainStorm, said the report in "Muscle & Nerve" was very promising. "This publication is an important milestone for BrainStorm as this is the first human data on NurOwn to be published in a prestigious scientific journal," he said. He said the company expects to finalize its Phase IIa clinical trial in the first half of 2014. According to the ALS Association, 5,600 people in the United States are diagnosed each year with the disease, which has severely disabled British physicist Stephen Hawking. Claim: BrainStorm says stem cells helped patient with ALS and MG.

A: A patient suffering from both ALS and myasthenia gravis (MG) showed significant improvement in cognitive and motor function following treatment with BrainStorm Cell Therapeutics adult stem cells, according to a published case report.
****
Q: Paragraph: Although Pfizer continues to test the drug, called dacomitinib, in another Phase III study, hopes for its success have now largely faded, according to ISI Group analyst Mark Schoenebaum. "We believe consensus expectations (for the drug) will be close to zero given today's readout" of unsuccessful trial results, Schoenebaum said in a research note. In one of the failed trials, called ARCHER 1009, patients given Pfizer's once-daily pill did not show improved survival without the cancer worsening, compared with Roche Holding AG's widely used Tarceva (erlotinib). Tarceva is the current standard of care in patients with mutated forms of a protein called Epidermal Growth Factor Receptor (EGFR). The protein plays a role in normal regulation of cell growth, but when mutated is believed to cause cells to proliferate and thereby help spur various types of cancer. Dacomitinib is designed to block several types of Epidermal Growth Factor receptors, while Tarceva and similar treatments for lung cancer target only one type of receptor. Cowen and Co had forecast annual sales of $500 million by 2020 for dacomitinib, if it were approved for lung cancer. That would make it a moderate-sized product for Pfizer, the largest U.S. drugmaker, which has annual revenue of $50 billion. Schoenebaum said there has been little investor interest in the drug and that Wall Street had expected it to generate annual sales of only $300 million by 2018. The second failed trial, named BR.26, involved patients that previously had failed to benefit from chemotherapy as well as from treatment with an EGFR inhibitor. Overall survival of patients taking the Pfizer drug was not prolonged in the study, compared with patients given a placebo. Pfizer said adverse events seen with dacomitinib were consistent with those seen in smaller earlier studies. In the meantime, Pfizer said dacomitinib is also being tested in a third late-stage trial, called ARCHER 1050, among patients with advanced non-small cell lung cancer who have not received prior treatment. The study will compare dacomitinib with Iressa (gefitinib), an EGFR inhibitor sold by AstraZeneca Plc. Results from that study are expected in 2015. Pfizer shares were little changed in morning trading on the New York Stock Exchange. Claim: Pfizer lung cancer drug fails in two large studies.

A:
Pfizer Inc on Monday said one of its experimental drugs had failed to meet its goals in two late-stage studies among patients who had received prior treatment for advanced non-small cell lung cancer, the most common form of the disease.
****